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Treatment of myelofibrosis (MF), a BCR-ABL–negative myeloproliferative neoplasm, is challenging. The only current
potentially curative option, allogeneic hematopoietic stem cell transplant, is recommended for few patients. The
remaining patients are treated with palliative therapies to manage MF-related anemia and splenomegaly. Identification
of a mutation in the Janus kinase 2 (JAK2) gene (JAK2 V617F) in more than half of all patients with MF has prompted
the discovery and clinical development of inhibitors that target JAK2. Although treatment with JAK2 inhibitors has been
shown to improve symptom response and quality of life in patients with MF, these drugs do not alter the underlying
disease; therefore, novel therapies are needed. The hedgehog (Hh) signaling pathway has been shown to play a role in
normal hematopoiesis and in the tumorigenesis of hematologic malignancies. Moreover, inhibitors of the Hh pathway
have been shown to inhibit growth and self-renewal capacity in preclinical models of MF. In a mouse model of MF,
combined inhibition of the Hh and JAK pathways reduced JAK2 mutant allele burden, reduced bone marrow fibrosis,
and reduced white blood cell and platelet counts. Preliminary clinical data also suggest that inhibition of the Hh
pathway, alone or in combination with JAK2 inhibition, may enable disease modification in patients with MF. Future
studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway
in patients with MF and will inform whether this combination approach can lead to true disease modification.
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Myelofibrosis (MF) is one of several BCR-ABL–negative
myeloproliferative neoplasms (MPNs), which are derived
from multipotent, hematopoietic myeloid progenitors
[1,2]. MF can be primary (PMF) or secondary to the
MPNs polycythemia vera (PV) or essential thrombocyth-
emia (ET) (post-PV or post-ET, respectively) [2]. MF is
characterized by stem cell–derived clonal myeloprolifera-
tion, abnormal cytokine expression, bone marrow fibrosis,
cytopenias, extramedullary hematopoiesis (eg, splenomeg-
aly), cachexia, and constitutional symptoms including
night sweats, fevers, weight loss, and fatigue [3-5]. Disease
complications also include infections, portal hypertension,
bleeding, extremity pain, and progression of disease with
blastic transformation, resembling acute leukemia [5-8].
MF is most commonly characterized by a mutation in
Janus kinase 2 (JAK2 V617F), which is present in ap-
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unless otherwise stated.and PMF, respectively [5,9]. The JAK2 V617F gain-of-
function mutation leads to constitutive activation of the
JAK/signal transducer and activation of transcription path-
way, which regulates the expression of genes involved in
proliferation, survival, and resistance to apoptosis (B-cell
CLL/lymphoma 2-like 1, myeloid cell leukemia sequence 1,
pim-1 oncogene, and cyclin D1; Figure 1A) [10]. Recently, a
high frequency of calreticulin mutations has been found in
JAK2 nonmutated MF [11,12]. Mutations in other genes,
including myeloproliferative leukemia virus oncogene,
SH2B adaptor protein 3, tet methylcytosine dioxygenase 2,
additional sex combs like 1 homolog (ASXL1), isocitrate
dehydrogenase (IDH), enhancer of zeste homolog 2
(EZH2), DNA (cytosine-5-)-methyltransferase 3 α, casitas
B-lineage lymphoma proto-oncogene, TP53, splicing factor
3b subunit 1, and serine/arginine-rich splicing factor 2
(SRSF2), have been found less frequently in patients with
MF [5]. Some of these mutations have been linked with
poor survival (ASXL1, EZH2, and SRSF2) and/or leukemic
transformation (ASXL1, SRSF2, and IDH) in patients with
PMF [13].tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 (See legend on next page.)
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Figure 1 Janus kinase 2 (JAK2)/signal transducer and activation of transcription (STAT) and hedgehog (Hh) signaling pathways in
normal development (A) and mechanisms of Hh signaling in cancer (B). (A) JAK/STAT signaling: the JAK2/STAT signaling pathway is
activated upon binding of a cytokine to its receptor, causing phosphorylation and activation of JAK2, which then recruits and phosphorylates
STATs. STATs dimerize, translocate to the nucleus, and activate target gene transcription. Hh signaling: in the absence of Hh ligand, patched
(PTCH) inhibits smoothened (SMO). Glioma-associated oncogene homolog 1/2 (GLI1/2) transcription factors are sequestered in the cytoplasm by
a repressor complex containing suppressor of fused (SUFU) and degraded. GLI3 is released from SUFU, processed into a repressor form (GLI3R),
and translocates to the nucleus to inhibit transcription of Hh pathway target genes. Hh signaling is activated upon binding of Hh to PTCH.
PTCH-mediated inhibition of SMO is relieved, and SMO activates release of GLIs from the SUFU complex. Activated GLIs (GLIA) then translocate to
the nucleus to regulate target gene transcription. (B) Several mechanisms of Hh pathway activation in cancer have been proposed, including
ligand independent (mutation driven) and ligand dependent (autocrine or paracrine) signaling. During autocrine signaling, Hh ligands produced
in the tumor activate Hh signaling in the same tumor cells. Paracrine signaling can involve tumor-to-stroma signaling or stroma-to-tumor
signaling (reverse paracrine). During tumor-to-stroma signaling, Hh ligands produced in the tumor activate Hh signaling in surrounding stromal
cells, which release growth hormones that in turn feed tumor growth. In the reverse model (stroma-to-tumor), which has been observed in
hematologic malignancies (lymphoma, myeloid neoplasms, and multiple myeloma), Hh ligands produced in stromal cells activate Hh signaling in
the tumor. BCL2, B-cell CLL/lymphoma 2; BCL2L1, BCL2-like 1; BMP, bone morphogenetic protein; CCND1, cyclin D1; MCL1, myeloid cell leukemia
sequence 1; PIM1, pim-1 oncogene.
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Scoring System Plus (DIPSS Plus), patients with MF are
assigned to one of 4 risk groups—low, intermediate-1,
intermediate-2, and high. These risk groups are based
on 8 factors independently associated with decreased
survival: age > 65 years, hemoglobin levels < 10 g/dL,
leukocyte count > 25 × 109/L, circulating blood blasts ≥
1%, constitutional symptoms, red blood cell transfusion,
platelet count < 100 × 109/L, and unfavorable karyotype
[14]. Median survival varies considerably according to
risk group, ranging in one study from 16 to 185 months
for high- and low-risk patients, respectively [14].
Current treatment strategies
The DIPSS Plus and Myeloproliferative Neoplasm Symp-
tom Assessment Form are used to inform treatment
regimen decisions [7,15]. For patients with asymptom-
atic low-risk or intermediate-1 disease, observation is gen-
erally recommended [5,16]. For symptomatic patients,
current therapies include allogeneic hematopoietic stem
cell transplant (HSCT) and palliative treatments that help
alleviate disease symptoms such as anemia and spleno-
megaly [5,16,17]. Allogeneic HSCT is associated with sig-
nificant risk of morbidity and mortality due to relapse,
infection, and graft-versus-host disease, and therefore is
recommended only for patients aged < 65 years with
intermediate- or high-risk disease [18]. Reduced-intensity
conditioning regimens have shown more favorable out-
comes but still pose a high risk for patients aged > 55 years
and patients with mismatched donors [19].
Therapies intended to treat MF-associated anemia in-
clude growth factors (eg, erythropoietin), androgens (eg,
danazol), and the immunomodulatory drugs (IMiDs) thal-
idomide (± prednisone), lenalidomide (± prednisone), and
pomalidomide (± prednisone) [20-26]. IMiDs have also
been shown to improve splenomegaly [27-29]. Other
agents used to treat MF-associated splenomegaly include
the nonspecific oral myelosuppressive agent hydroxyurea,the oral alkylators melphalan and busulfan, and the purine
nucleoside analog 2-CdA [30-32]. Hydroxyurea is a choice
for splenomegaly in patients with MF as well [5]. Although
generally well tolerated, hydroxyurea can lead to myelo-
suppression, which can exacerbate MF-associated anemia
[14,16].
Based on the finding that the majority of patients with
MF have a mutation in JAK2, numerous inhibitors of
JAK2 (ruxolitinib [INCB018424], fedratinib [SAR302503;
TG101348], lestaurtinib [CEP-701], momelotinib [CYT387],
pacritinib [SB1518], AZD1480, BMS-911543, gandotinib
[LY2784544], AT9283, and XL019) have been developed
and are being evaluated in clinical trials. Of note, JAK inhib-
itors also have activity in JAK2 nonmutated MF/PMF
[33,34]. Ruxolitinib, an inhibitor of JAK1 and JAK2, was ap-
proved in 2011 by the US Food and Drug Administration
(FDA) for use in patients with intermediate- or high-risk
MF (PMF, post-PV MF, and post-ET MF) and in 2012 by
Health Canada and the European Medicines Agency for the
treatment of MF-related splenomegaly and symptoms
[35-37]. JAK2 inhibitors differ according to their specificity
for JAK2 and have variable efficacy and toxicity profiles
[5,17].
Unmet need in the treatment of MF
Currently, the only potentially curative therapy for patients
with MF is allogeneic HSCT [16,38]. Due to treatment-
related morbidity and mortality, HSCT is recommended
for patients with intermediate-2– or high-risk disease who
are fit enough to undergo the procedure. The majority of
patients with MF are treated with palliative therapies, which
improve disease symptoms rather than altering the natural
history of disease [17]. The discovery of the JAK2 gain-of-
function mutation, JAK2 V617F [39-42], followed by the
development and approval of ruxolitinib has marked a new
era in the treatment of MF, providing improved symptom-
atic responses and quality of life in comparison with trad-
itional therapies [36,37,43-45]. However, treatment with
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modification–JAK2 inhibitors do not improve bone marrow
fibrosis and most provide limited reduction of JAK2 V617F
allelic burden [16,17]. Ruxolitinib appears to block inflam-
matory cytokine activity rather than stem cell–derived
clonal myeloproliferation, which is the primary driver of
the disease [46]. Therefore, disease resistance can ensue fol-
lowing an initial response to JAK2 inhibition [16,46]. In
addition, treatment-related anemia may exacerbate preex-
isting MF-related anemia [33,43,44].
To further improve the responses to JAK2 inhibitors,
various combinations have been clinically tested. For ex-
ample, combination of JAK2 inhibitors with agents that im-
prove anemia (eg, IMiDs) or target signaling pathways
involved in proliferation, survival, and self-renewal may fur-
ther improve the outcome of patients with MF [26,47-49].
Combinations of JAK2 inhibitors with inhibitors of the
hedgehog (Hh) pathway, which plays a role in the mainten-
ance of cancer stem cells [50], could provide an avenue
of targeting stem cell–derived clonal myeloproliferation
(which evades JAK2-targeted monotherapy) [51]. Other
combination partners, including hypomethylating agents
(Tibes, unpublished observation) and Aurora-kinase inhib-
tors have also been proposed [52]. The preclinical rationale
and current clinical evidence supporting use of Hh path-
way–targeted therapies in the treatment of patients with
MF will be discussed herein.
Rationale for targeting the Hh pathway in MF
The Hh pathway and its role in hematopoiesis
The Hh signaling pathway plays a role in proliferation, dif-
ferentiation, and survival during embryonic developmentFigure 2 Role of hedgehog (Hh) signaling in hematopoiesis. Preclinica
numerous stages and processes of hematopoiesis, including primitive hem
differentiation (lymphoid and myeloid lineages)—and maintenance of HSC
not clear. HSC, hematopoietic stem cell.and in tissue and stem cell maintenance in the adult
[50,53]. Hh signaling is initiated when one of 3 ligands–
sonic hedgehog (SHH), Indian hedgehog (IHH), or
desert hedgehog (DHH)–binds to patched (PTCH), a
12-transmembrane receptor, relieving its inhibition of
smoothened (SMO), a 7-transmembrane G-like protein–
coupled receptor (Figure 1A). SMO then translocates to
the primary cilium and activates the glioma-associated
oncogene homolog (GLI) transcription factors, a process
that involves their release from a repressor complex in-
cluding suppressor of fused. Once released, GLIs translo-
cate to the nucleus to regulate the transcription of target
genes including GLI1/2, PTCH, cyclin D1, and B-cell CLL/
lymphoma 2.
Hh signaling is required during hematopoiesis (Figure 2);
however, its exact role is not completely understood and
may differ depending on the stage of hematopoiesis, cell
type (stem, primitive, or differentiated cell), and physio-
logical state [54]. During primitive hematopoiesis,
when embryonic mesoderm is committed to becoming
hematopoietic precursors (eg, erythrocytes) and blood
islands begin to form [55,56], Ihh is expressed in the
visceral endoderm surrounding the epiblast and in the
endodermal layer of the mature yolk sac and induces
the expression of Ptch1, Smo, and Gli1 within these tis-
sues [57]. Murine Ihh knockout mice and in vitro stud-
ies in Ihh-deficient embryonic stem cell lines suggest
that Ihh is required for hematopoiesis and vasculogen-
esis [57-60]. Survival of half of Ihh−/− mice and the obser-
vation that Smo−/− mice die earlier suggest that Dhh and/
or Shh may also play a role in primitive hematopoiesis and
vasculogenesis [57,61].l studies suggest that the Hh signaling pathway may be involved in
atopoiesis, definitive hematopoiesis—establishment, proliferation, and
s. The exact role for Hh signaling at each of these stages/processes is
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only in establishing definitive hematopoiesis, which is
characterized by formation of multipotent hematopoietic
stem cells (HSCs), but also in the proliferation and differ-
entiation of HSCs (Table 1) [62-70]. Activated Hh signal-
ing through loss of Ptch leads to increased HSC formation
and activity [64,66], enhanced recoverability following
treatment with 5-fluorouracil [65,66], and increased regen-
eration capacity [65,66]. Conversely, loss of pathway activ-
ity through mutation of the downstream effector, Gli1, in
mice leads to decreased proliferation of long-term HSCs
and myeloid progenitors, reduced myeloid differentiation,
and delayed recovery following 5-fluorouracil treatment
[69]. Interestingly, reduced HSC activity (through loss of
Gli1) led to increased engraftment. Together, these studies
suggest that inhibition of the Hh pathway at different
nodes (ie, Smo vs Gli1) affects hematopoiesis differently.Table 1 Preclinical evidence for Hh pathway involvement in he
Preclinical model
Activated Hh signaling • Ptch mutant chimeric explant cultures
• Ptch+/− mice vs wild-type mice
(bone marrow, fetal liver cells)
• Conditional loss of Ptch in adult murine HSCs
• Conditional loss of Ptch in adult murine
non-HSCs
Impaired Hh signaling • Ihh−/− knockout mice
• Dhh-deficient mouse model
• Conditional deletion of Smo in fetal and
adult hematopoietic and endothelial cells
(Vav driven Cre-Lox system)
• Smo-depleted mouse stromal cells
• Gli1null mice
• Human pluripotent stem cells
5-FU 5-fluorouracil, AGM aorta-gonad-mesonephros, Dhh desert hedgehog, Gli gliom
hedgehog, Ptch, patched, Smo smoothened.The role of Hh signaling in long-term HSCs is not well
understood—several groups have reported conflicting re-
sults (Table 1); however, in each study, activated Hh sig-
naling led to aberrant hematopoiesis [65-67]. There have
also been some discrepancies in studies involving deletion
of Smo, based on the temporal expression pattern of the
experimental driver used (embryogenesis vs adulthood)
and its specificity (hematopoietic and endothelial tissue vs
HSCs, lymphocytes, and liver cells) [65,68,73,74]. Disrup-
tion of Hh signaling earlier and in more tissues affected
HSC function, whereas disruption of Hh signaling in adult
HSCs had no effect, suggesting that Hh signaling may be
important during early definitive hematopoiesis.
Numerous studies have also presented evidence implicat-
ing the Hh pathway in the maintenance or homeostasis of
hematopoietic precursors [72,75-79]. Activated Hh signal-
ing in nonhematopoietic cells (ie, epithelial cells or marrowmatopoiesis and in progenitor expansion and maintenance
Evidence
• Hh signaling from ventral tissues surrounding the AGM was shown
to induce and increase HSC activity in a time-dependent manner [64]
• Hh signaling enhanced regeneration potential in short-term
HSCs through increased HSC number [66], enhanced recoverability
following 5-FU treatment [65,66], and increased regeneration
capacity [65,66]
• In long-term HSCs with activated Hh signaling, repopulating
cells were eventually exhausted in the bone marrow [66],
whereas fetal liver cells showed long-term regeneration capacity [65]
• Ptch deletion in HSCs did not cause Hh pathway activation
or affect hematopoiesis [67]
• Ptch deletion in non-HSCs led to aberrant hematopoiesis,
including apoptosis of lymphoid progenitors in epithelial cells,
increased numbers of lineage-negative bone marrow cells,
and increased mobilization of myeloid progenitors in bone
marrow niche cells [67]
• Terminal erythroid differentiation was defective despite
normal production of HSCs and progenitor cells [62]
• Dhh was shown to regulate normal and stress-induced
erythropoiesis by preventing erythropoiesis differentiation
in the spleen and bone marrow [71]
• Decreased stem cell activity was observed despite
normal number and differentiation of HSCs [68]
• Differentiation of hematopoietic progenitors was
impaired—the number of myeloid progenitors was
increased at the expense of lymphoid progenitors [72]
• Caused reduced expression of factors involved in
B-cell development or osteoblast differentiation
• Decreased proliferation of long-term HSCs and myeloid
progenitors, reduced myeloid differentiation, and delayed
recovery following 5-FU treatment were observed [69]
• Gli3R, the repressor form of Gli3, was shown to be necessary
and sufficient in the initiation and regulation of adult
hematopoietic specification [70]
a-associated oncogene, Hh hedgehog, HSC hematopoietic stem cell, Ihh Indian
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increase in the number of lineage-negative bone marrow
cells and increased mobilization of myeloid progenitors
[67]. Inhibition of Hh signaling in marrow stromal cells led
to impaired differentiation of B-lymphoid cells from
hematopoietic progenitors—the number of myeloid pro-
genitors was increased at the expense of lymphoid progeni-
tors [72]. These and several other studies suggest that Hh
signaling may be required in a noncell autonomous manner
where Hh signaling functions in the nonhematopoietic
bone marrow cells (ie, stroma or epithelial cells) surround-
ing HSCs to maintain, particularly myeloid, hematopoietic
precursors (Figure 2) [67,72,76-79].
The Hh pathway in MF and other hematologic malignancies
To date, preclinical data on the potential role of the Hh
pathway in MF are limited. However, in one study, expres-
sion of GLI1 and PTCH1 were shown to be increased up to
100-fold in granulocytes isolated from patients with MPNs
compared with control granulocytes [51]. The Hh pathway
was also shown to be up-regulated in a mouse bone mar-
row transplant model [51]. In this same model, mice were
treated with vehicle, ruxolitinib, or a combination of ruxoli-
tinib and the SMO inhibitor sonidegib (LDE225), for
28 days [51]. Combination therapy resulted in increased ef-
ficacy in MPNs—causing a greater reduction of mutant al-
lele burden in the bone marrow, reduced bone marrow
fibrosis, lower white blood cell count, and lower platelet
count than treatment with vehicle or ruxolitinib alone
(Table 2). Moreover, in the Gata1low mouse model of MF,Table 2 Pharmacologic inhibition of SMO in MF, leukemia, lym
Model Inhibitor Ef
Murine MF model [51] Sonidegib (LDE225) • C
m
c




BCR-ABL+ cells [82-85] Vismodegib (GDC-0449), sonidegib • I
• E
• E
AML cell lines and primary cells [86] PF-04449913 • I
• A




Sonidegib, BMS-833923 • P
t
MM CD138− tumor stem cells [91] Cyclopamine • S
ALDH aldehyde dehydrogenase, ALL acute lymphocytic leukemia, AML acute myeloi
myelofibrosis, MM multiple myeloma, SMO smoothened, TKI tyrosine kinase inhibitogene expression analysis of the spleen and bone marrow
identified alterations in the expression of bone morpho-
genetic protein 4, an indirect target of the Hh pathway, fur-
ther supporting a role for Hh signaling in MF [80,81].
There are many preclinical studies implicating the Hh
pathway in the pathogenesis of other hematologic malig-
nancies and solid tumors [92]. Aberrant Hh signaling in
cancer is postulated to occur through ligand-independent
and ligand-dependent mechanisms (Figure 1B) [93].
Ligand-independent or mutation-driven signaling occurs
when mutations in Hh pathway components—loss-of-
function mutations in the negative regulators PTCH and
SUFU (suppressor of fused), or gain-of-function mutations
in the positive regulator SMO—lead to constitutive path-
way activation within tumor cells. This type of signaling
has been observed in basal cell carcinoma (PTCH and
SMO mutations) [94,95], medulloblastoma (PTCH and
SUFU mutations) [96], and rhabdomyosarcoma (PTCH
and SUFU loss of heterozygosity) [97].
Ligand-dependent mechanisms involve autocrine or
paracrine Hh signaling [93]. During autocrine Hh signal-
ing, tumor cells both secrete and respond to Hh—this type
of Hh signaling has been identified in chronic myeloid
leukemia (CML), small cell lung cancer, pancreatic cancer,
breast cancer, and glioma [93]. Paracrine Hh signaling
involves tumor-to-stroma or stroma-to-tumor (reverse
paracrine) signaling. During tumor-to-stroma paracrine
signaling, tumor cells produce and secrete Hh ligands
which activate Hh signaling in surrounding stromal cells.
Activated stromal cells release growth hormones which inphoma, and MM preclinical models and cell lines
fect
aused reduction of mutant allele burden in bone marrow, reduced bone
arrow fibrosis, and reduced white blood cell and platelet counts when
ombined with ruxolitinib in comparison with ruxolitinib treatment alone
educed LSC numbers and secondary transplantation capacity
n BCR-ABL+ cells
rolonged survival in treated mice, alone [68] or in combination
ith TKI therapy [65]
nhibited cell growth, self-renewal, and serial transplantation
nhanced activity of BCR-ABL–targeted TKIs
nhanced control of TKI-resistant cells [83,84]
nhibited proliferation and induced cell death (minimally)
ttenuated leukemia initiation potential in serial transplantation experiments
ecreased self-renewal as evidenced by decreased numbers of ALDH+ cells;
ignificantly decreased secondary colony formation in vitro and leukemic
ngraftment in vivo [87]
nduced apoptotic cell death (reduced levels of p53 and cyclin D1) [90]
roliferation and apoptosis were not affected; data support hypothesis
hat Hh signaling may affect self-renewal [88]
ignificantly inhibited cell growth relative to control
d leukemia, CML chronic myeloid leukemia, LSC leukemic stem cell, MF
r.
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tumor-to-stroma paracrine signaling has been observed in
pancreatic, colon, and prostate cancers [93]. Evidence for
reverse paracrine signaling (stroma-to-tumor) in which
Hh ligand produced in bone marrow stromal cells acti-
vates Hh signaling in surrounding tumor cells, has been
reported for hematologic malignancies such as lymphoma,
myeloid neoplasms, and multiple myeloma (MM) [91,98].
In addition, the Hh pathway has been implicated in the
maintenance and differentiation of cancer stem cells in
CML, B-cell acute lymphocytic leukemia (B-ALL), and
MM [50,99,100]. Moreover, up-regulation of Hh path-
way components has been observed in the tumor stem
cells of numerous hematologic malignancies, including
BCR-ABL+ leukemic stem cells (LSCs) [65,68], clono-
genic B-ALL cells [87], CD34+ acute myeloid leukemia
(AML)– and myelodysplastic syndromes (MDS)–de-
rived cells [77], and MM CD138− tumor stem cells [91].
Pharmacologic inhibition of SMO has been shown to
inhibit leukemogenesis through inhibition of LSC cell
growth, self-renewal, and secondary transplantation
capacity and induction of cell death in CML, AML, and
ALL models (Table 2) [65,68,82-88]. Hh signaling has
also been implicated in the progression of CML in
mouse bone marrow transplant models [65,68]. Consti-
tutively active Smo was shown to increase the frequency
of CML stem cells and accelerate disease progression [68].
Conversely, genetic loss or pharmacologic inhibition of
Smo significantly impaired CML progression and pro-
longed survival [65,68]. These data suggest that the Hh
signaling pathway plays a role in numerous hematologic
malignancies, including MF, and its inhibition may block
tumor stem cell growth and disease progression.
Clinical studies of HH pathway inhibitors in patients with
MF and other hematologic malignancies
Several Hh pathway inhibitors that target SMO have dem-
onstrated single-agent efficacy in patients with ligand-
independent tumors [101-105], including vismodegib,
which was approved by the FDA in 2012 for the treatment
of patients with locally advanced or metastatic basal cell
carcinoma [101,106]. Patients with Hh-activated medullo-
blastoma have also responded to treatment with vismode-
gib and the SMO inhibitor sonidegib [102,104,105].
Conversely, limited single-agent activity has been observed
in ligand-dependent solid tumors—this lack of activity
may be due in part to the contributions of other signaling
pathways and stromal factors [107]. To date, saridegib
(IPI-926), sonidegib, and PF-04449913 are the only SMO
inhibitors that have been or are being tested in patients
with MF (NCT01371617, NCT01787552, and NCT00
953758, respectively) (Table 3). A phase 2 study of saride-
gib in patients with MF (NCT01371617) was halted
following evaluation of an initial cohort of 12 patients—the level of clinical activity observed with saridegib did not
meet the prespecified expansion criteria [108]. No further
data have been reported. Data from a phase 1 trial of
single-agent PF-04449913 presented at the American Soci-
ety of Hematology in 2011 showed that PF-04449913 dem-
onstrated activity in patients with refractory, resistant, or
intolerant select hematologic malignancies, including MF
(NCT00953758) [109]. The dose-limiting toxicity at 80 mg
once daily was grade 3 hypoxia and pleural effusion. Of 6
patients with MF treated with PF-04449913, 5 achieved
stable disease and 1 achieved clinical improvement with >
50% reduction in extramedullary disease. This patient
remained on the study after 385 days and showed a spleen
reduction from 10 to 3.5 cm over 8 weeks. Another patient
achieved a marked reduction in bone marrow fibrosis.
Sonidegib is currently being investigated in combin-
ation with ruxolitinib in patients with MF in a phase 1/2
study (NCT01787552). Patients with PMF, post-PV MF,
or post-ET MF are eligible. Primary endpoints include
determination of dose-limiting toxicities, maximum tol-
erated dose and/or recommended phase 2 dose of the
combination, and proportion of patients achieving ≥
35% decrease in spleen volume. Secondary endpoints
include safety, pharmacokinetics, improvement in bone
marrow fibrosis, and change in total symptom score
(modified Myelofibrosis Symptom Assessment Form v
2.0), JAK2 V617F allele burden, cytokine levels, and
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire 30.
These inhibitors, as well as the SMO inhibitors vismo-
degib (first in class) and BMS-833923, are being investi-
gated in other hematologic malignancies, including ALL,
AML/MDS, CML, and MM (Table 3) [111].
Assessment of Hh pathway inhibition in the clinic
For maximization of the potential of Hh pathway inhibitor
therapy in patients with MF and related myeloid malignan-
cies such as MDS and AML, and demonstration of a bene-
fit over current therapies, it will be important to develop a
method to assess the association of Hh pathway inhibitor
activity with efficacy. In other tumor types, GLI1 expression
has been used to determine changes in Hh pathway activity
and confirm targeted inhibition in patients treated with
SMO inhibitors [99,103,104,112,113]. In patients with MF,
AML, or CML, one study showed that gene expression
analysis of bone marrow CD34+ LSCs before and after
treatment with PF-04449913 showed up-regulation of
growth arrest specific 1 and kinesin family member 27, 2
negative regulators of the Hh signaling pathway [113].
Although changes in the expression of downstream Hh
pathway components can be used to detect Hh pathway re-
pression, a more appropriate measure of Hh pathway
inhibitor activity in patients with MF is evidence of disease
modification through histopathologic (bone marrow
Table 3 Clinical trials of SMO inhibitors in MF and other hematologic malignancies
Smo inhibitor Patient population Phase Combination partner Primary endpoint Statusa ClinicalTrials.gov identifier
Sonidegib (LDE225) PMF, post-PV MF, post-ET MF 1/2 Ruxolitinib DLTs, MTD and/or RP2D (of combination),
proportion of patients achieving≥ 35%
decrease in spleen volume
Recruiting NCT01787552
Acute leukemias 2 CR, CRi Recruiting NCT01826214
CML 1 Nilotinib DLT, MTD, RP2D Recruiting NCT01456676
PF-04449913 Refractory, resistant, or intolerant
select hematologic malignancies
1 DLT Completed NCT00953758 [109]
AML/MDS 1/2 Chemotherapy DLT, CRR, OS Recruiting NCT01546038
Acute leukemias 2 Post–stem cell transplant Relapse-free survival Recruiting NCT01841333
MDS 2 ORR Recruiting NCT01842646
Vismodegib (GDC-0449) AML/MDS 1b/2 ORR Recruiting NCT01880437
Lymphomas (B cell, CLL) 2 ORR Recruiting NCT01944943
MM 1 Post–stem cell transplant Change in MM CSC counts Ongoing, not recruiting NCT01330173
BMS-833923 CML 1/2 Dasatinib RP2D for combination Completed NCT01218477
2 Dasatinib MMR Ongoing, not recruiting NCT01357655 [89]
MM 1 Lenalidomide + dexamethasone
or bortezomib
DLT, MTD, RP2D Completed NCT00884546 [110]
AML acute myeloid leukemia, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, CR complete remission, CRi complete remission with incomplete blood count recovery, CRR complete response rate, CSC
cancer stem cell, DLT dose-limiting toxicity, ET essential thrombocythemia, MDS myelodysplastic syndromes, MF myelofibrosis, MM multiple myeloma, MMR major molecular response, MTD maximum tolerated dose,
ORR overall response rate, OS overall survival, PMF primary myelofibrosis, PV polycythemia vera, RP2D recommended phase 2 dose, SMO smoothened.
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http://www.jhoonline.org/content/7/1/18fibrosis) and cytogenetic (JAK2 V617F allele burden) re-
mission. In patients with MF with JAK2 V617F mutations,
change in allele burden following treatment with a Hh
pathway inhibitor would be an appropriate marker for
stem cell inhibition. Similarly, for patients with MDS or
AML disease-initiating mutations, reduction in allele bur-
den would indicate a possible on-target effect. In patients
without mutations, identification of an appropriate marker
is yet to be accomplished. Sustained responses following
treatment discontinuation may also reflect disease modifi-
cation. Ultimately, in order to assess the efficacy of future
targeted therapies, a combination of endpoints, including
disease-specific histopathologic (ie, reduction of fibrosis)
and molecular (ie, allele burden reduction) changes and
clinical efficacy (ie, improvement in blood counts),
should be considered. Future preclinical studies in JAK2
V617F–negative MF and correlative data from the ongoing
trials of Hh pathway inhibitors in patients with MF may
better define the optimal method for determination of effi-
cacy and identification of predictive and pharmacodynamic
biomarkers in patients treated with Hh pathway inhibitors.
Conclusions
Despite recent advances in the treatment of MF, lack of
true disease modification following treatment with current
therapies warrants the identification of novel therapies. In-
hibitors of the Hh signaling pathway, which has been
implicated in the maintenance of HSCs, have shown pre-
liminary activity as single agents or in combination with
ruxolitinib in preclinical and clinical studies in MF. A clin-
ical study combining the Hh pathway inhibitor sonidegib
with the JAK2 inhibitor ruxolitinib in patients with MF is
currently underway. In addition, we are currently working
on preclinical studies and the development of a clinical
trial to test the combination of Hh pathway inhibitors with
the hypomethylating agent 5-azacitidine (Tibes, personal
communication). These and future studies will test the hy-
pothesis that targeting pathways involved in stem cell
maintenance will not only extend the duration of benefit
but will also lead to true disease modification in patients
with MF treated with JAK2 inhibitors, as well as test their
activity in other hematologic malignancies.Abbreviations
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